+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Multiplexed Diagnostics Market by Method (High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays), Application (Allergic Diseases, Autoimmune Diseases, Cardiology), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968780
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Multiplexed Diagnostics Market size was estimated at USD 14.98 billion in 2023, USD 17.36 billion in 2024, and is expected to grow at a CAGR of 16.62% to reach USD 43.97 billion by 2030.

Multiplexed diagnostics allows simultaneous detection and analysis of multiple biomarkers or targets in a single assay or test. Multiplexed diagnostics incorporate multiple detection channels or probes within a single test, enabling the detection of multiple analytes simultaneously. This approach offers several advantages, including increased efficiency, cost-effectiveness, and conservation of sample volume. Multiplexed diagnostics can provide a more comprehensive understanding of the disease or condition being analyzed by considering multiple biomarkers or targets, allowing for better accuracy and reliability in diagnostics. Multiplexed diagnostics have become more popular due to growing demand for improved diagnostic technologies, rising incidences of cancer and other infectious diseases, and greater private-public expenditure for genomes and personalized medicine. However, limited multiplexing levels, possible cross-sensitivity between single detection sites, and lack of trained healthcare professionals for handling multiplexed diagnostic equipment impede the utilization of multiplexed diagnostics. In addition, introducing new and advanced multiplexed diagnostic tools and increasing emphasis on R&D activities to generate next-generation sequencing solutions is expected to create tremendous growth opportunities for the multiplexed diagnostics market development.

Regional Insights

The favorable government initiatives and funding to develop and improve healthcare offerings across the EMEA have expanded the scope of multiplexed diagnostics across the region. The investment of USD 347 million (GBP 260 million) by the government of the U.K. to support healthcare research & development and diagnostics has been creating a strong landscape for multiplexed diagnostics across the EMEA. The new advancements by market companies in multiplexed diagnostics solutions across the Americas and the initiative by Biomedical Advanced Research and Development Authority (BARDA) to develop technologies for rapid and multiplexed across the U.S. has been rapidly fostering the applications of multiplexed diagnostics across the Americas. Moreover, the increasing demand for cost-effective diagnosis services across the Asia-Pacific region has contributed to multiplexed diagnostics' rapid expansion. Furthermore, initiatives taken by government bodies to enhance public awareness regarding diagnostic services, the availability of highly skilled professionals, and the high acceptance of advanced diagnostic technologies are expected to propel market growth in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiplexed Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiplexed Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiplexed Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Inc., Akoya Biosciences, AusDiagnostics by R-Biopharm, Baxter International Inc, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMérieux SA, Cardinal Health, Chembio, ChromaCode, Inc., Danaher Corporation, Delta Diagnostics BV, F. Hoffmann-La Roche AG, Genabio Diagnostics Inc., Hologic, Inc., Illumina, Inc., Leica Biosystems, Medtronic PLC, Merck KGaA, Novartis AG, PCR Biosystems, QIAGEN N.V., Quansys Biosciences Inc., Seegene, Inc., Siemens Healthineers, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services.

Market Segmentation & Coverage

This research report categorizes the Multiplexed Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Method
    • High Density Multiplexed Assays
    • Low Density Multiplexed Assays
    • Mid-Density Multiplexed Assays
    • Very High Density Multiplexed Assays
  • Application
    • Allergic Diseases
    • Autoimmune Diseases
    • Cardiology
    • Infectious Diseases
    • Oncology
  • End-User
    • Academic Research
    • Clinical Research
    • Diagnostic Labs
    • Hospitals
    • Pharma Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Multiplexed Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiplexed Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the Multiplexed Diagnostics Market?
  4. What is the market share of the leading vendors in the Multiplexed Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the Multiplexed Diagnostics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Multiplexed Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for advanced diagnostic technology coupled with increased in prevalence of cancers and other infectious diseases
5.1.1.2. Rise in private-public funding for genomics & personalized medicine
5.1.1.3. Demand for automated equipment & analytical systems
5.1.2. Restraints
5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
5.1.3. Opportunities
5.1.3.1. Introduction of new and advanced multiplexed diagnostic tools
5.1.3.2. Increasing emphasis on R&D activities to generate next-generation sequencing solutions
5.1.4. Challenges
5.1.4.1. Lack of trained healthcare professionals for handling multiplexed diagnostic equipment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Multiplexed Diagnostics Market, by Method
6.1. Introduction
6.2. High Density Multiplexed Assays
6.3. Low Density Multiplexed Assays
6.4. Mid-Density Multiplexed Assays
6.5. Very High Density Multiplexed Assays
7. Multiplexed Diagnostics Market, by Application
7.1. Introduction
7.2. Allergic Diseases
7.3. Autoimmune Diseases
7.4. Cardiology
7.5. Infectious Diseases
7.6. Oncology
8. Multiplexed Diagnostics Market, by End-User
8.1. Introduction
8.2. Academic Research
8.3. Clinical Research
8.4. Diagnostic Labs
8.5. Hospitals
8.6. Pharma Companies
9. Americas Multiplexed Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Multiplexed Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Multiplexed Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
12.3.1.2. Aptitude Receives up to USD 54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
12.3.1.3. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
12.3.2. New Product Launch & Enhancement
12.3.2.1. Paper-Based Test for Multiplexed Sensing of Biomarkers Developed
12.3.2.2. ALiA BioTech’s One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line
12.3.3. Investment & Funding
12.3.3.1. Delta Diagnostics raises €5.25 million (USD 5.76 million) in Series A Funding to Revolutionize Biosensing Technology
12.3.3.2. Proxim Diagnostics Announces Strategic Investment from bioMérieux
12.3.3.3. Synthetic biology startup D-Nome raises USD 1.5 million in funding from Ankur Capital, Campus Fund
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AccuBioTech Co., Ltd.
13.1.3. Agilent Technologies, Inc.
13.1.4. Akoya Biosciences
13.1.5. AusDiagnostics by R-Biopharm
13.1.6. Baxter International Inc
13.1.7. Becton, Dickinson and Company
13.1.8. Bio-Rad Laboratories, Inc.
13.1.9. bioMérieux SA
13.1.10. Cardinal Health
13.1.11. Chembio
13.1.12. ChromaCode, Inc.
13.1.13. Danaher Corporation
13.1.14. Delta Diagnostics BV
13.1.15. F. Hoffmann-La Roche AG
13.1.16. Genabio Diagnostics Inc.
13.1.17. Hologic, Inc.
13.1.18. Illumina, Inc.
13.1.19. Leica Biosystems
13.1.20. Medtronic PLC
13.1.21. Merck KGaA
13.1.22. Novartis AG
13.1.23. PCR Biosystems
13.1.24. QIAGEN N.V.
13.1.25. Quansys Biosciences Inc.
13.1.26. Seegene, Inc.
13.1.27. Siemens Healthineers
13.1.28. Thermo Fisher Scientific, Inc.
13.1.29. West Pharmaceutical Services
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. MULTIPLEXED DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MULTIPLEXED DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
FIGURE 8. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MULTIPLEXED DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 6. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 11. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 17. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 33. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 36. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 50. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 53. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 59. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 77. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 87. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 90. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 93. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 96. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 99. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 105. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 114. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 117. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 120. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 132. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 141. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 150. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 151. MULTIPLEXED DIAGNOSTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • Akoya Biosciences
  • AusDiagnostics by R-Biopharm
  • Baxter International Inc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Cardinal Health
  • Chembio
  • ChromaCode, Inc.
  • Danaher Corporation
  • Delta Diagnostics BV
  • F. Hoffmann-La Roche AG
  • Genabio Diagnostics Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Leica Biosystems
  • Medtronic PLC
  • Merck KGaA
  • Novartis AG
  • PCR Biosystems
  • QIAGEN N.V.
  • Quansys Biosciences Inc.
  • Seegene, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
  • West Pharmaceutical Services

Methodology

Loading
LOADING...

Table Information